Phase 1 N=30 Food-Effect Study in Healthy Participants
Healthy
Primary: Pharmacokinetics - Cmax (ng/mL) — 394.7; 322.8 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=9 The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects
Healthy
Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of SSP-004184 Under Fasted and Fed Conditions — 112,236.7; 154,676.6 ng*hr/mL
Phase 1 N=16 Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)
Healthy Adult Subjects
Primary: Area Under the Concentration Versus Time Curve From Zero up to Infinity (AUC0-inf) of Edaravone — 2165; 2209; 2073; 1955 ng·h/mL
Phase 1 N=18 To Evaluate the Food Effect on Relative Bioavailability of RP6530 in Healthy Volunteers
Healthy
Primary: Pharmacokinetic Parameters (Area Under the Plasma Concentration Versus Time Curve (AUC)) — 5277.01; 6726.99 nanogram*hour per millilitre (ng*h/mL) — p=0.0002
Phase 1 N=24 Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers
Healthy Volunteers
Primary: Maximum Observed Concentration in Plasma (Cmax) of Pexidartinib — 4580; 7090; 3870 ng/mL
Phase 1 N=18 Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate
Epilepsy
Primary: Cmax (BIA 2-005) — 10973; 11044; 11022 ng/mL
Phase 1 N=21 A Study to Assess the Food Effect on Bioavailability of Metformin/Gliclazide in Healthy Participants
Healthy
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Metformin and Gliclazide — 4974.2507; 8556.7752; 21192.1682; 21815.4021…
Phase 1 N=30 A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants
Healthy
Primary: Area Under the Plasma-Concentration Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of PF-07104091 for Treatment A, B, and C — 10920; 10720; 11200…
Phase 1 N=76 A Study in Healthy Men to Find Out How Well Different Doses of BI 764122 Are Tolerated and Whether Food Affects the Amount of BI 764122 in the Blood
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events — 6.3; 0.0; 16.7; 0.0 Percentage of participants
Phase 1 N=24 Food Effect and Bioequivalence Study of Simufilam Tablets in Healthy Volunteers
Healthy Volunteers
Primary: Cmax — 698; 715; 755; 680 ng/mL
Phase 1 N=32 Relative Bioavailability and Food Effect Study of CVN424
Parkinson's Disease
Primary: Area Under the Concentration-time Curve From Time 0 to the Time of the Last Measured Non Zero Concentration (AUC0-t) of CVN424 Suspension Fasted and Tablet Fasted…
Phase 1 N=18 Pharmacokinetics of BI 409306 After a High Fat, High Caloric Meal and After a Single Oral Dose Given at Bed Time in Healthy Volunteers
Healthy
Primary: Maximum Measured Concentration of BI 409306 in Plasma (Cmax) — 183; 175; 150 Nanomole per litre
Phase 1 N=12 Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants
Healthy Participants
Primary: Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-07321332 — 43360; 35860 Nanogram*hour…
Phase 1 N=36 Food Effect Study of Febuxostat XR in Healthy Participants
Gout
Primary: Cmax: Maximum Observed Plasma Concentration for Febuxostat XR 80 mg in Fed (Regimen A) and Fasted (Regimen C) States — 1020.0000; 1531.6286 ng/mL
Phase 3 N=12 Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects
Clinical Pharmacology
Primary: AUC (0-72): Area Under the Plasma Concentration-time Curve From Time 0 to 72 Hours Postdose for Unchanged SYR-322 (SYR-322Z) — 1494.9; 1472.8 nanogram*milliliter per…
Phase 1 N=25 TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants
Healthy
Primary: Cmax: Maximum Observed Plasma Concentration for TAK-020 — 104.182; 44.800; 139.522; 6.012 nanogram per milliliter (ng/mL) — p=<0.001
Phase 1 N=12 A Phase 1 Food Effect Study of TAK-536TCH Final Formulation Tablet
Hypertension
Primary: Cmax: Maximum Plasma Concentration for TAK-536, Its Metabolites (M-I and M-II) and Hydrochlorothiazide (HCTZ) — 1912.0; 1783.7; 448.3; 455.3 nanogram per milliliter…
Phase 1 N=12 A Study to Test How Food Influences the Amount of BI 1323495 in the Blood of Healthy Men
Healthy
Primary: Area Under the Concentration-time Curve of BI 1323495 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point — NA; NA nanomol (nmol) * hours (h) /…
Phase 1 N=18 A Study in Healthy People to Test How BI 1015550 is Taken up in the Body When Given With or Without Food
Healthy
Primary: Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) (AUC0-tz) — 2225.20; 2563.65…
Phase 1 N=18 A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants
HIV Infections
Primary: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0 to Inf]) for GSK3640254-Part 1 — 36.94; 36.88 Hours*microgram per milliliter
Phase 1 N=12 Relative Bioavailability and Food Effect Study of IX-01 Capsules in Healthy Men
Healthy Participants
Primary: Relative Bioavailability (Frel) of a Capsule Compared to a Liquid Formulation of IX-01 While Fasting, as Calculated by a Ratio of Area Under the Plasma Concentration…
Phase 1 N=12 A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults
Healthy Participants
Primary: Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PF-07284890 in Plasma, Comparison of…
Phase 1 N=10 Study to Evaluate Potential Food Effects
Healthy
Primary: Cmax — 2567.9; 3568.9 ng/mL
Phase 1 N=14 A Study in Healthy Men to Test Whether Food Affects the Amount of BI 894416 in the Blood
Healthy
Primary: Area Under the Concentration-time Curve of BI 894416 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 4436.69; 4458.63 nanomole…
Phase 1 N=14 A Study in Healthy Subjects to Evaluate Pharmacokinetics and Food Effect After Dosing of GS-248
Pharmacokinetic
Primary: Cmax — 508.6; 384.5; 289.5; 499.5 nmol/L
Phase 1 N=24 Piperaquine Granule Formulation Relative Bioavailability and Food Effect Study in Healthy Volunteers.
Malaria
Primary: Relative Bioavailability (Frel) of the Maximum Observed Plasma Concentration (Cmax) of the PQP Dispersible Granule Compared to the PQP Hard Tablet in the Fasted State…
Phase 1 N=18 Relative Bioavailability of BI 1467335 Tablet and Oral Solution, and Food Effect on Tablet in Healthy Male Subjects
Healthy Volunteers
Primary: AUC0-tz of BI 1467335 — 3.90; 2.24; 2.49 nanomole*hour/Liter (nmol*h/L)
Phase 1 N=91 Safety and Pharmacokinetics of Single Rising Doses of BI 705564 and Food Effect on BI 705564 in Healthy Male Subjects
Healthy
Primary: Number of Participants With Drug-related Adverse Events (AEs) — 3; 1; 4; 1 Participants
N/A N=30 Evaluation of Food Effect on the Pharmacokinetics of Sustained Release Metformin in Healthy Indian Volunteers
Diabetes Mellitus, Type 2
Primary: Maximum Observed Concentration (Cmax) — 884.297; 963.384; 942.653 Nanograms per milliliter (ng/mL) — p=0.1413
Phase 1 N=18 Phase 1 Study to Determine the Effects of Food on the Pharmacokinetic Profile of PBT2
Healthy Volunteers
Primary: Area Under the Concentration-Time Curve (AUC 0-t) — 1490.0; 1273.0 h*ng/mL